Comparing efficacy and safety of P013, a proposed pertuzumab biosimilar, with the reference product in HER2-positive breast cancer patients: a randomized, phase III, equivalency clinical trial
Allahyari, Abolghasem, Ehsanpour, Ali, Najafi, Behrouz, Ansarinejad, Nafiseh, Mehrzad, Valiollah, Kalantari, Behjat, Raafat, Jahangir, Ghadiany, Mojtaba, Shahi, Farhad, Gharib, Behrooz, Moazed, Vahid, Khosravi, Adnan, Mirpour, Mir Hossein, Salari, Sina, Mortazavizadeh, Seyedmohammadreza, Nekoyi, Amirabbas, Khani, Mohsen, Sadeghi, Alireza, Gharib, Sirus, Bary, Alireza, Mirzania, Mehrzad, Haghighat, Shirin, Razavi, Seyed Mohsen, Emami, Seyed Amir Hossein, Hosseinzadeh, Mehran, Mirbolouk, Mahdi, Sadighi, Sanambar, Shahrasbi, Abdolali, Esfahani, Ali, Gity, Masoumeh, Anjidani, Nassim, Kafi, Hamidreza, Najafi, Safa
Published in BMC cancer (07.09.2022)
Published in BMC cancer (07.09.2022)
Get full text
Journal Article
Correction: Comparing efficacy and safety of P013, a proposed pertuzumab biosimilar, with the reference product in HER2-positive breast cancer patients: a randomized, phase III, equivalency clinical trial
Allahyari, Abolghasem, Ehsanpour, Ali, Najafi, Behrouz, Ansarinejad, Nafseh, Mehrzad, Valiollah, Kalantari, Behjat, Raafat, Jahangir, Ghadiany, Mojtaba, Shahi, Farhad, Gharib, Behrooz, Moazed, Vahid, Khosravi, Adnan, Mirpour, Mir Hossein, Salari, Sina, Mortazavizadeh, Seyedmohammadreza, Nekoyi, Amirabbas, Khani, Mohsen, Sadeghi, Alireza, Gharib, Sirus, Bary, Alireza, Mirzania, Mehrzad, Haghighat, Shirin, Razavi, Seyed Mohsen, Emami, Seyed Amir Hossein, Hosseinzadeh, Mehran, Mirbolouk, Mahdi, Sadighi, Sanambar, Shahrasbi, Abdolali, Esfahani, Ali, Gity, Masoumeh, Anjidani, Nassim, Kaf, Hamidreza, Najaf, Safa
Published in BMC cancer (22.12.2022)
Published in BMC cancer (22.12.2022)
Get full text
Journal Article